IAVI and its partners are advancing a diverse porfolio of select preventive HIV vaccine candidates.
IAVI details its organizational strategic vision for the period 2011-2015 made.
Engage with IAVI on your social media networks.
This is an open-label study with an MVA vector-based HIV-1 clade A candidate vaccine, MVA.HIVA, in HIV-uninfected healthy male and female volunteers at low risk of HIV infection. On Day 0 and Day 21 study participants will receive a single intradermal injection of 5x10^7 pfu in 0.1ml in the latero-dorsal aspect over the deltoid muscle.
International AIDS Vaccine Initiative. All rights reserved. International AIDS Vaccine Initiative, IAVI and the IAVI logo are trademarks of the International AIDS Vaccine Initiative, Inc.